Supplement Industry Plants Longtime Use Flag As US Looks At Expanding Peptide Bulk Drugs List

The supplement industry is lobbying to include peptides in the FDA's compounding bulk drug list expansion, seeking to legitimise longtime use of peptide ingredients under a regulatory umbrella currently reserved for pharmaceuticals. The move could reshape how peptide-based supplements are classified and regulated in the US market.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.